Advances in science have led to the development of multiple biologics and small molecules
for the treatment of inflammatory bowel diseases (IBDs). This growth in advanced medical …

Objective: To review the pharmacologic and clinical profile of etrasimod in the treatment of
ulcerative colitis (UC). Data sources: A PubMed search was conducted from inception to …

Background Ustekinumab is approved for ulcerative colitis (UC). Aims To assess the
durability of ustekinumab in patients with UC and its short‐term effectiveness, durability and …

ETHNOPHARMACOLOGICAL RELEVANCE The efficacy of Shaoyao decoction (SYD), a
traditional Chinese medicine prescription, in alleviating colonic mucosal inflammation in …

Background Metformin exerts anti-inflammatory properties through a positive effect on
oxidative stress, gut barrier integrity, and the gut microbiota. Our aim was to evaluate the …

Introduction While an association between hidradenitis suppurativa (HS) and inflammatory
arthritis has been reported in clinical studies, the potential link between HS and gout …

Background: Few studies have compared the efficacy and safety of second-line biological
therapies in ulcerative colitis (UC) patients with prior exposure to anti-tumor necrosis factor …

A Retocolite Ulcerativa (RCU) é uma condição de inflamação crônica do cólon que
apresenta um curso de recidivas e remissões o que requer abordagens terapêuticas que …

LINKED CONTENT This article is linked to Kochhar et al papers. To view these articles, visit
https://doi. org/10.1111/apt. 17570 and https://doi. org/10.1111/apt. 17750

Letter: Tofacitinib, vedolizumab and ustekinumab in patients with ulcerative colitis—Authors'
reply Page 1 Aliment Pharmacol Ther. 2023;58:1243. wileyonlinelibrary.com/journal/apt …